HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases

Mycoses

Volumn 49, Issue SUPPL. 1, 2006, Pages 17-22

  Müller, Carsten ^a   Arndt, Margit ^a   Queckenberg, Christian ^a   Cornely, Oliver A ^a   Theisohn, Martin ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Antifungal agents; Bioavailability; HPLC; Itraconazole; Posaconazole

Indexed keywords

ACETONITRILE; AMIODARONE; AMISULPRIDE; ANTIFUNGAL AGENT; CLOMIPRAMINE; CLOZAPINE; ETIRACETAM; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LAMOTRIGINE; LICARBAZEPINE; NORCLOMIPRAMINE; NORTRIPTYLINE; OLANZAPINE; PHENOBARBITAL; POSACONAZOLE; PRIMIDONE; QUETIAPINE; VENLAFAXINE; VORICONAZOLE;

ARTICLE; CONTROLLED STUDY; DRUG ANALYSIS; DRUG BIOAVAILABILITY; DRUG SENSITIVITY; HEMATOLOGIC DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; HEMATOLOGIC DISEASES; HUMANS; MYCOSES; TRIAZOLES;

EID: 33748581308     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2006.01297.x     Document Type: Article

References (13)

1. Bow EJ. Long-term antifungal prophylaxis in high-risk hematopoietic stem cell transplant recipients. Med Mycol 2005; 43 (Suppl. 1): S277-87.
2. van Burik JA. Role of new antifungal agents in prophylaxis of mycoses in high risk patients. Curr Opin Infect Dis 2005; 18: 479-83.
3. Steinbach WJ, Benjamin DK. New antifungal agents under development in children and neonates. Curr Opin Infect Dis 2005; 18: 484-9.
4. Herbrecht R. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int J Clin Pract 2004; 58: 612-24.
5. Keating GM. Posaconazole. Drugs 2005; 65: 1553-67; discussion 1568-9.
6. Cuenca-Estrella M, Gomez-Lopez A, Mellado E et al. Head-to-head comparison of the activities of currently available antifungal agents against 3378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50: 917-21.
7. Cuenca-Estrella M, Gomez-Lopez A, Garcia-Effron G et al. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Chemother 2005; 49: 1232-5.
8. Ezzet F, Courtrey R, Krishna G et al. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005; 44: 211-20.
9. Courtney R, Poir S, Laughlin M et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47: 2788-95.
10. Ullmann AJ, Cornely OA, Burchardt A et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50: 658-66.
11. Al-Rawithi S, Hussein R, Al-Moshen I et al. Expedient microdetermination of itraconazole and hydroxyitraconazole in plasma by high-performance liquid chromatography with fluorescence detection. Ther Drug Monit 2001; 23: 445-8.
12. Kim H, Likhari P, Kumari P et al. High-performance liquid chromatographic analysis of the anti-fungal agent SCH 56592 in dog serum. J Chromatogr B Biomed Sci Appl 2000; 738: 93-8.
13. Petraitiene R, Petraitis V, Groll AH et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001; 45: 857-69.